[DOI] [PubMed] [Google Scholar] 112.Bailey AJM, Li HO, Tan MG, Cheng W, Dover JS
Adding to the turmoil, later the same week, Eli Lilly reported that its oral GLP-1 candidate, orforglipron, outperformed Novo Nordisk's Rybelsus (oral semaglutide) in the head-to-head phase III ACHIEVE-3 study in type II diabetes (T2D)
Transfections and cell culture Human and pGLP-1R cDNAs were isogenically integrated into FlpIn-Chinese hamster ovary (FlpInCHO) cells (Invitrogen) and selection of receptor-expressing cells accomplished by treatment with 600 g/ml hygromycin B as described previously 46
[DOI] [PMC free article] [PubMed] [Google Scholar] 32.Yaez M.J., Leiva A
Injection-site reactions (redness, itching, mild swelling) occur in approximately 1015% of patients and typically resolve with site rotation and slower injection speed